As Celestica Inc. continues to gain traction amid improvingDemand/">Demand/">Demandin advanced electronicsManufacturing/">Manufacturing/">ManufacturingandData Centerinfrastructure, the Tradr 2X Long CLS Daily ETF (CSEX) offers a tactical vehicle for traders aiming toCapitalize/">Capitalize/">Capitalizeon short-term upside movements in the stock.Celestica Inc. operates within a dynamic segment of the technologySupply/">Supply/">Supplychain, benefiting …

Vinay Lochav | 29 April 2026

QNTM Surges 21% as Unbuzzd Wellness Names CEO to Drive U.S. Expansion

ALeadershipAppointment Drives a Sharp Market Response

Nitish Kishor | 29 April 2026

News

General Motors Beats Earnings Forecasts but Tariff and War Costs Weigh on Outlook

Sherwin-Williams Extends Margin Streak but Raw Material Costs Cloud Second Half

T-Mobile Widens Competitive Lead as Network Differentiation Drives Financial Outperformance

Visa's Strongest Revenue Growth in Over a Decade Signals Structural Momentum

The Night That Could Move Markets: Alphabet, Amazon, Microsoft, and Meta Report Together

Brent Crude Surges Past USD 117 as Hormuz Fears and Inventory Shock Grip Global Energy Markets

The US Just Became a Net Oil Exporter. The Iran War Made It Happen.

Avalyn Pharma IPO: A Lung-Targeted Inhaled Therapy Platform Enters the Public Markets

Riding the Upside Momentum: Understanding the Mechanics of a 2X Leveraged Long Strategy on Celestica

QNTM Surges 21% as Unbuzzd Wellness Names CEO to Drive U.S. Expansion

Latest News

CoreWeave (NASDAQ:CRWV), Astera Labs (NASDAQ:ALAB) Jump as Nasdaq 100 Adds Five New Stocks

Intel (NASDAQ: INTC) Receives Rare Double Upgrade From BofA as Agentic AI Reshapes CPU Demand Landscape

SpaceX IPO (NASDAQ: SPCX) Creates Public Valuation Benchmark That Reshapes Pricing Across Entire Space Sector

Caribou Biosciences (NASDAQ: CRBU) CB-011 Multiple Myeloma Data Shows 92% ORR and 91% MRD-Negative Rate in Phase 1

Caribou Biosciences (NASDAQ: CRBU) CAR-T Platform Posts 82% ORR in Phase 1 Lymphoma Trial, BofA Reaffirms Buy

Aditxt (NASDAQ: ADTX) $150M Ignite Proteomics Spin-Off Plan Triggers Institutional Activity and Insider Exits